FDA SAE reporting guidance – Clinical Research Made Simple

SOP for SAE Reporting to Regulators

digi — Wed, 27 Aug 2025 09:48:49 +0000

SOP for SAE Reporting to Regulators

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-SAE-Reporting-to-Regulators”
},
“headline”: “SOP for SAE Reporting to Regulators in Clinical Trials”,
“description”: “This SOP provides standardized procedures for reporting serious adverse events (SAEs) to regulatory authorities, ensuring compliance with ICH GCP, FDA, EMA, CDSCO, and WHO requirements for expedited safety reporting.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for SAE Reporting to Regulators

Department	Clinical Research
SOP No.	CR/SAE/043/2025
Supersedes	NA
Page No.	1 of 22
Issue Date	26/08/2025
Effective Date	01/09/2025
Review Date	01/09/2026

Purpose

The purpose of this SOP is to describe the procedures for reporting serious adverse events (SAEs) to regulatory authorities in compliance with global requirements. It ensures timely reporting, accurate documentation, and subject safety.

Scope

This SOP applies to investigators, sponsors, and CROs responsible for SAE submission to regulatory agencies. It covers expedited, periodic, and follow-up safety reporting, including electronic submissions via regulatory portals.

Responsibilities

Principal Investigator (PI): Notifies sponsor of SAEs and provides required documentation for regulatory submission.
Sponsor/CRO: Responsible for submitting SAEs to regulatory authorities within required timelines.
Regulatory Affairs Department: Manages submissions to FDA, EMA, CDSCO, and other authorities.
QA Officer: Reviews compliance with reporting requirements during audits and inspections.

Accountability

The sponsor is accountable for ensuring SAE regulatory reporting is accurate, timely, and compliant with global requirements. The PI remains accountable for initial SAE reporting to the sponsor.

Procedure

1. Initial SAE Notification
PI reports SAE to sponsor within 24 hours of awareness.
Sponsor initiates regulatory assessment for expedited submission.

2. Reporting Timelines
Fatal or life-threatening SAEs: Submit to regulatory authority within 7 calendar days.
All other SAEs: Submit within 15 calendar days.
Follow-up reports: Submit as soon as new information is available.

3. Submission Process
Prepare SAE Case Report using regulatory-compliant template.
Submit electronically via FDA Safety Reporting Portal, EudraVigilance (EMA), or SUGAM (CDSCO).
Maintain submission receipts in TMF and ISF.

4. Documentation
Maintain SAE Submission Log (Annexure-1).
File acknowledgment receipts from authorities.
Reconcile SAE submissions with safety database.

5. Reconciliation and Close-Out
Reconcile SAE site reports, sponsor records, and regulatory submissions.
Ensure all submissions are complete before study close-out.

6. Archiving
Archive SAE submissions and correspondence for minimum 5 years post-trial or as per regulatory requirements.

Abbreviations

SOP: Standard Operating Procedure
PI: Principal Investigator
SAE: Serious Adverse Event
CRO: Clinical Research Organization
QA: Quality Assurance
TMF: Trial Master File
ISF: Investigator Site File
FDA: Food and Drug Administration
EMA: European Medicines Agency
CDSCO: Central Drugs Standard Control Organization

Documents

SAE Submission Log (Annexure-1)
SAE Case Report Template (Annexure-2)
Regulatory Acknowledgment Record (Annexure-3)

References

Version: 1.0

Approval Section

Prepared By	Rajesh Kumar, Clinical Research Associate
Checked By	Sunita Reddy, QA Officer
Approved By	Dr. Anil Sharma, Principal Investigator

Annexures

Annexure-1: SAE Submission Log

Date	Subject ID	Event	Regulatory Authority	Submission Date	Acknowledgment
12/09/2025	CT2025-SITE01-101	Severe allergic reaction	FDA	13/09/2025	Yes

Annexure-2: SAE Case Report Template

Subject ID	Event Description	Date of Onset	Causality	Expectedness	Outcome
CT2025-SITE01-101	Severe allergic reaction	12/09/2025	Possibly related	Unexpected	Recovered

Annexure-3: Regulatory Acknowledgment Record

Date	Regulatory Authority	Acknowledgment No.	Verified By
13/09/2025	FDA	ACK-FDA-2025-1122	QA Officer

Revision History

Revision Date	Revision No.	Revision Details	Reason for Revision	Approved By
26/08/2025	00	Initial version	New SOP creation	Head, Clinical Research

For more SOPs visit: Pharma SOP

SOP for SAE Reporting to Sponsor

digi — Tue, 26 Aug 2025 06:03:53 +0000

SOP for SAE Reporting to Sponsor

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-SAE-Reporting-to-Sponsor”
},
“headline”: “SOP for SAE Reporting to Sponsor in Clinical Trials”,
“description”: “This SOP provides procedures for timely and accurate reporting of serious adverse events (SAEs) to the sponsor in clinical trials, ensuring compliance with ICH GCP, FDA, EMA, CDSCO, and WHO requirements.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for SAE Reporting to Sponsor

Department	Clinical Research
SOP No.	CR/SAE/041/2025
Supersedes	NA
Page No.	1 of 22
Issue Date	26/08/2025
Effective Date	01/09/2025
Review Date	01/09/2026

Purpose

The purpose of this SOP is to establish standardized procedures for reporting serious adverse events (SAEs) to the sponsor in clinical trials. This ensures subject safety, regulatory compliance, and timely communication for expedited safety reporting obligations.

Scope

This SOP applies to investigators, study coordinators, and other authorized site personnel involved in SAE identification and reporting. It covers initial SAE notification, follow-up reporting, causality assessment, and sponsor communication requirements.

Responsibilities

Principal Investigator (PI): Responsible for SAE assessment, initial reporting, and follow-up updates to the sponsor.
Study Coordinator: Completes SAE reporting forms, ensures supporting documentation is submitted, and maintains ISF/TMF records.
Sponsor/CRO: Reviews SAE reports, ensures regulatory submission within required timelines, and reconciles data with the safety database.
Quality Assurance Officer: Audits SAE reporting records during monitoring visits and inspections.

Accountability

The PI is accountable for timely and accurate SAE reporting to the sponsor. The sponsor is accountable for ensuring further submission to regulatory authorities and global safety databases.

Procedure

1. Initial Reporting
Notify the sponsor of any SAE within 24 hours of site awareness.
Use the sponsor-provided SAE Form (Annexure-1).
Provide minimum required details: subject ID, event description, date of onset, and outcome.

2. Follow-Up Reporting
Submit follow-up information including diagnostic results, hospital records, and updated outcomes.
Update SAE Form (Annexure-1) with each follow-up.

3. Causality and Expectedness Assessment
PI assesses causality (related or unrelated) and expectedness.
Record assessment on SAE Causality Form (Annexure-2).

4. Documentation
File SAE Forms, correspondence, and acknowledgment receipts in ISF and TMF.
Maintain SAE Log (Annexure-3).

5. Reconciliation
Reconcile SAE data with sponsor’s safety database at regular intervals.
Resolve discrepancies prior to trial close-out.

6. Archiving
Archive SAE records for a minimum of 5 years post-trial or as per local regulations.